Cerebellar tDCS in Children With Autism Spectrum Disorder
University of Texas Southwestern Medical Center · with United States Department of Defense · NCT04446442
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 4–17 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 60
- US sites recruiting
- 2
- Study start
- June 4, 2019
- Record last updated
- June 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive behaviors and hyperactivity.
Being studied: tDCS
Conditions: Autism Spectrum Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 4-17 years old
- Diagnosed with ASD and ADOS-2
- IQ Score no less than 70 (1.5 Standard Deviations below the mean)
- Language Level (Speech consists of, at minimum, flexible, spontaneous, simple, sentences)
Exclusion Criteria
- Brain implants, metal implants, pacemakers, or biomedical devices
- Diagnosis of epilepsy
- Hearing or visual impairments
- History of brain injury
- Known brain abnormalities not associated with ASD
Recruiting US locations
Children's Medical Center
Dallas, TX 75235
University of Texas Southwestern
Dallas, TX 75390
Study contacts (from the official record)
- Peter Tsai, MD, PhD · 214-648-3577 · peter.tsai@utsouthwestern.edu
- Amy Magallanes · 214-648-5155 · amy.magallanes@utsouthwestern.edu
Similar studies in Texas
All healthy volunteers studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75